适形光子与质子乳腺及区域淋巴结照射时代的最佳靶区勾画与治疗技术
该研究在代表性患者CT上按RTOG、ESTRO和RADCOMP图谱勾画靶区,生成3D CRT、VMAT和PBSPT计划,并将102例乳腺癌患者的389个CT阳性且18F-FDG高摄取区域淋巴结映射至计划。结果显示3D CRT覆盖良好,而VMAT和PBSPT在遵循RTOG或ESTRO图谱时对高位腋窝、锁骨上区和内乳淋巴结存在低剂量风险,RADCOMP图谱可改善覆盖但心、肺剂量略增。
要点
- VMAT和PBSPT按RTOG或ESTRO图谱勾画时,高位腋窝、锁骨上区和内乳淋巴结存在低剂量风险。
- RADCOMP图谱使上述区域覆盖达89%-100%,但心、肺剂量略增。
- 高危乳腺癌区域淋巴结照射需全面靶区勾画以避免VMAT/PBSPT低剂量。
核心结论
- 高危乳腺癌区域淋巴结照射采用VMAT或PBSPT时,若未进行全面靶区勾画,高位腋窝、锁骨上区和内乳淋巴结存在低剂量风险。
研究设计与样本
- 在代表性患者CT上按RTOG、ESTRO和RADCOMP图谱勾画靶区,并生成3D CRT、VMAT和PBSPT计划。
- 回顾102例局部晚期(n=51)和转移性(n=51)乳腺癌患者的PET/CT,映射389个CT阳性且18F-FDG高摄取区域淋巴结。
- 区域淋巴结包括腋窝284个、锁骨上60个、内乳45个;18F-FDG高摄取淋巴结落入95%等剂量线内视为充分覆盖。
主要发现
- 3D CRT计划提供 excellent 的区域淋巴结覆盖,所有计划中低位腋窝淋巴结覆盖≥99%。
- 遵循RTOG和ESTRO图谱时,VMAT和PBSPT计划对高位腋窝(78%-92%)、锁骨上(52%-75%)和内乳(84%-89%)的18F-FDG高摄取淋巴结存在低剂量。
- 使用RADCOMP图谱对这些区域覆盖达89%-100%,但心、肺剂量略增。
- 图谱引导的VMAT/PBSPT计划累积淋巴结覆盖为ESTRO(89%/88%)、RTOG(93%/91%)、RADCOMP(98%/96%)。
关键数值与推荐
- 18F-FDG高摄取区域淋巴结落入95%等剂量线内视为充分覆盖。
- 低位腋窝淋巴结在所有3D CRT计划中覆盖≥99%。
- RTOG和ESTRO图谱下VMAT/PBSPT对高位腋窝覆盖78%-92%、锁骨上52%-75%、内乳84%-89%。
- RADCOMP图谱下上述区域覆盖89%-100%。
- 累积淋巴结覆盖:ESTRO 89%/88%,RTOG 93%/91%,RADCOMP 98%/96%(VMAT/PBSPT)。
临床怎么用
- 高危乳腺癌区域淋巴结照射采用VMAT或PBSPT时,应进行全面靶区勾画以降低高位腋窝、锁骨上区和内乳淋巴结低剂量风险。
- 可参考RADCOMP图谱改善区域淋巴结覆盖,但需注意心、肺剂量略增。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Regional nodal irradiation improves disease-free and distant disease-free survival in patients with high-risk breast cancer (BC). Trials demonstrating this used 2- or 3-dimensional conformal radiation therapy (2-dimensional or 3-dimensional [3D] conformal radiotherapy [CRT]) fields based on bony anatomy. Modern volumetric-modulated arc therapy (VMAT) and pencil beam scanning proton therapy (PBSPT) may underdose regional nodes (RNs) not contoured but covered by 3D CRT. Multiple atlases guide modern treatment planning. This study addresses the risk of underdosing when relying on published atlases and treating with 3D CRT, VMAT, and PBSPT. METHODS AND MATERIALS: Targets per the Radiation Therapy Oncology Group (RTOG), European Society for Radiotherapy and Oncology (ESTRO), and Radiotherapy Comparative Effectiveness Consortium (RADCOMP) atlases were contoured on a representative patient CT scan. 3D CRT plans based on anatomic borders and VMAT and PBSPT plans for each set of target volumes were generated. Positron emission tomography/computed tomography (PET/CT) scans were reviewed. CT-positive and 18F-fluorodeoxyglucose (18F-FDG)-avid RNs (n = 389) were mapped from 102 patients with locally advanced (n = 51; median 2; range, 1-8 nodes) and metastatic (n = 51; median 4; range, 1-19 nodes) BC: axillary (AX; n = 284), supraclavicular (SCV; n = 60), and internal mammary nodal (IMN; n = 45). 18F-FDG-avid RNs falling within the 95% isodose line were considered adequately covered. RESULTS: 3D CRT plans provided excellent RN coverage. Low AX nodes were covered (≥99%) in all plans. Underdosing of 18F-FDG-avid RNs falling in the high AX (78%-92%), SCV (52%-75%), and IMN (84%-89%) volumes was observed following the RTOG and ESTRO atlases for VMAT and PBSPT plans. Use of the RADCOMP atlas provided coverage of these areas (89%-100%) with slightly increased heart and lung doses. Atlas guided VMAT/PBSPT plans provided cumulative nodal coverage as follows: ESTRO (89%/88%), RTOG (93%/91%), and RADCOMP (98%/96%). CONCLUSIONS: VMAT and PBSPT for regional nodal irradiation in patients with high-risk BC risks underdosage in the high AX, SCV, and IMN nodal regions unless comprehensive target delineation is performed.
引用
- Kowalski ES, Feigenberg SJ, Cohen J, et al. Optimal Target Delineation and Treatment Techniques in the Era of Conformal Photon and Proton Breast and Regional Nodal Irradiation. Pract Radiat Oncol. 2019. PMID: 31786234. doi:10.1016/j.prro.2019.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。